This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
by Zacks Equity Research
Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
by Zacks Equity Research
Here we highlight a few companies that are focused on developing treatments for prostate cancer.
AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia
by Zacks Equity Research
AstraZeneca's (AZN) rare blood cancer candidate receives approval from the FDA for relapsed or refractory hairy cell leukemia (HCL) in patients who have received at least two prior systemic therapies.
Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study
by Indrajit Bandyopadhyay
Spectrum Pharma (SPPI) amends poziotinib study protocol to include two cohorts to evaluate it in first-line lung cancer.
Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus
by Ekta Bagri
Here we take a look at companies with approved immunotherapy therapies or pipeline candidates for the treatment of widely prevalent NSCLC.
Pfizer's Drug Combo Betters Survival in Kidney Cancer Study
by Zacks Equity Research
Pfizer's (PFE) phase III study on a combination of its cancer drugs, Bavencio and Inlyta meets primary endpoint of improving PFS in advanced kidney cancer patients with PD-L1+ tumors.
The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson
Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus
by Zacks Equity Research
Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.
AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
AstraZeneca (AZN) and partner Amgen's asthma candidate, tezepelumab gets Breakthrough Therapy designation from the FDA.
AstraZeneca Up This Year So Far on Favorable Pipeline Updates
by Zacks Equity Research
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
AstraZeneca's Lupus Drug Misses Primary Endpoint in Study
by Zacks Equity Research
AstraZeneca's (AZN) phase III study, evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus, does not meet primary endpoint.
4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline
by Kinjel Shah
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Bausch (BHC) Resubmits NDA for Duobrii for Plaque Psoriasis
by Zacks Equity Research
Bausch Health Companies Inc. (BHC) resubmits its NDA for plaque psoriasis drug, Duobrii to the FDA and the agency has set a PDUFA action date of Feb 15, 2019.
AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon
by Zacks Equity Research
AstraZeneca (AZN) gains EU approval for a new formulation of its diabetes medicine Bydureon ??? Bydureon BCise.
Bausch (BHC) Gets FDA Approval for Altreno for Acne Vulgaris
by Zacks.com
Bausch (BHC) advances its dermatology portfolio with the FDA approval of Altreno for acne vulgaris.
Merck, Eisai Get EU Approval for Lenvima Label Expansion
by Zacks Equity Research
Merck (MRK) and Japanese partner Eisai gain an approval from the EU for Lenvima label expansion. The anti-cancer drug receives the regulatory body's nod for first-line treatment of unresectable HCC.
AstraZeneca's Bevespi Unimpressive in Phase III COPD Study
by Zacks Equity Research
AstraZeneca's (AZN) inhaler, Bevespi Aerosphere, fails to demonstrate superiority over Glaxo's Arono in a phase III COPD study.
Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs
by Zacks Equity Research
Allergan (AGN) gets CRL for uterine fibroids candidate, Esmya. Merck (MRK) and Bristol-Myers' (BMY) PD-L1 inhibitors get FDA approval for expanded labels.
Novartis Breast Cancer Drug Meets Primary Goal in Phase III
by Zacks Equity Research
Novartis' (NVS) late-stage candidate, BYL719, meets primary endpoint in SOLAR trial on advanced breast cancer patients.
Ironwood's Linzess Gets Approval in Japan for New Indication
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) along with its partner Astellas Pharma announces approval of Linzess in Japan for a new indication - chronic constipation.
Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC
by Zacks Equity Research
AstraZeneca (AZN) receives approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the label expansion of Tagrisso.
Merck, Eisai Get FDA Approval for Lenvima Label Expansion
by Zacks Equity Research
Merck (MRK) and Japanese partner Eisai gains an FDA approval for Lenvima label expansion. The anti-cancer drug receives the regulatory body's nod for the first line treatment of unresectable HCC.
Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication
by Zacks Equity Research
Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.
Top Research Reports for Cisco, AstraZeneca & Enbridge
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems (CSCO), AstraZeneca (AZN) and Enbridge (ENB).
Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.